Statement: A patient who had an oophorectomy in the last month would not be eligible for the primary trial.
Primary_evidence: Inclusion Criteria:   Histologically confirmed triple-negative (estrogen, progesterone, and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease   Participant who in the Investigator's opinion requires combination therapy for their disease   Life expectancy of greater than or equal to (>/=)12 weeks Exclusion Criteria:   Previous chemotherapy for metastatic breast cancer   Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain)   Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment